All In Biotech

Drug Trial Radar · NCT06971523

A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of CTS3497 in Patients With MTAP Deficient Advanced Solid Tumors and Lymphomas

Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

224

Planned (sponsor's estimate)

Start

Dec 25, 2024

Primary completion

Dec 31, 2028

Study completion Jun 30, 2029

Sponsor

Sponsor type
Industry
First posted
May 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.

Conditions

  • Solid Tumor
  • Lymphoma

Interventions

  • CTS3497Drug

    CTS3497: Orally via capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Number of Patients Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days after the first administration.
  2. Phase I: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Baseline through 28 days after the end of treatment, estimated up to 52 weeks.
  3. Phase II: Objective Response Rate (ORR)Time frame: up to 48 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.